Enveda has secured $311 million in funding, valuing the AI-driven biotech company at $2 billion. The company is advancing clinical trials for drugs targeting skin conditions and weight maintenance after discontinuing GLP-1 therapies.
Bessemer Venture Partners has announced a new $5.75 billion fund focused on investing in AI-native companies, which they believe are expanding faster than any other technology sector in history.
Anthropic describes Opus 5.5 as their highest-performing model yet, combining top-tier capabilities with more affordable pricing, matching the performance level of Fable.
OpenAI is introducing two new AI models, GPT-6 Sol and Luna, which share the same foundational technology as Astra. These models are designed to be more cost-effective while reducing errors, enhancing the overall user experience.
The seven-year-old company has secured $350 million in Series E funding to accelerate its data-as-a-service model, responding to the growing market need for AI training data.
Angle Health has expanded its customer base to 5,000 small businesses and achieved profitability by offering level-funded health insurance plans that provide cost-effective coverage solutions.
Bain Capital Ventures is channeling its new $1.6 billion fund to support early-stage entrepreneurs focused on advancing artificial general intelligence (AGI) and developing the essential infrastructure for its seamless operation.
Google, Nvidia, Anthropic, and Emerald AI have joined forces to identify and secure 100 GW of electrical grid capacity to support the expansion of data centers, addressing the growing demand for digital infrastructure.
Newly disclosed court documents reveal that Microsoft internally criticized OpenAI's approach to data collection, labeling it as "theft," despite both companies accessing paywalled New York Times materials to compile datasets. Internal warnings highlighted concerns that these practices could severely harm publishers' business models.
Anthropic and OpenAI plan to integrate independent safety evaluators within their AI research teams. While this move is praised for offering rare access to internal processes, experts caution that effective oversight hinges on genuine independence, transparency, and the introduction of formal regulations.
